Kenji Sawa

Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase‐positive non‐small‐cell lung cancer

Yasutaka Ihara, Hisako Yoshida, Ayumi K. Shintani, 2023, Cancer science.

Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer

J. Tanizaki, K. Sakai, H. Hayashi, 2024, British Journal of Cancer.

NOTCH1 and CREBBP co‐mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR‐mutated NSCLC: translational research of phase III IMPACT study

Y. Ohde, H. Akamatsu, H. Tada, 2023, Molecular oncology.